
What is claimed is:

1. Use of an EZH2 inhibitor in the manufacture of a first medicament and use of a standard of care agent in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combinatorial therapy to treat a germinal center-derived lymphoma,

wherein the EZH2 inhibitor is EPZ-6438 having the following formula:



(EPZ-6438) or a pharmaceutically acceptable salt thereof;

wherein the standard of care agent is selected from GDC0068, GSK1070916, GSK2126458, GSK690693, JQ1, Ruxolitinib, Enzastaurin, and GSK1070916.

2. The use of claim 1, wherein the germinal center-derived lymphoma is an EZH2 wild type germinal center B-cell lymphoma; or an EZH2 mutant germinal center B-cell lymphoma.

3. The use of claim 1, wherein the germinal center-derived lymphoma is diffuse large B-cell lymphoma, follicular lymphoma, Burkitt's lymphoma or Non-Hodgkin's Lymphoma of germinal center B cell subtype.

4. The use of claim 1, wherein the lymphoma is Primary Mediastinal Large B-Cell Lymphoma (PMBCL).

5. The use of claim 4, wherein the PMBCL is a mutant EZH2.

6. The use of claim 4, wherein the PMBCL is wild-type EZH2.

7. The use of any one of claims 1-6, wherein the EZH2 inhibitor is a pharmaceutically acceptable salt of EPZ-6438.

8. The use of any one of claims 1-7, wherein the first medicament is to be administered to a subject at a dose of about 100 mg to about 3200 mg daily.

9. The use of any one of claims 1-7, wherein the first medicament is to be administered to a subject at a dose of about 100 mg BID to about 1600 mg BID.

10. The use of any one of claims 1-7, wherein the first medicament is to be administered to a subject at a dose of about 100 mg BID, 200 mg BID, 400 mg BID, 800 mg BID, or about 1600 mg BID.

11. The use of any one of claims 1-10, wherein the first medicament is to be administered orally.


12. The use of any one of claims 8-10, wherein the subject is a human being.

13. The use of any one of claims 1-12, wherein the first medicament and the second medicament are to be administered simultaneously or sequentially.

14. The use of any one of claims 1-13, wherein the first medicament is to be administered prior to administration of the second medicament.

15. A pharmaceutical composition comprising an EZH2 inhibitor and a standard of care agent,

wherein the EZH2 inhibitor is EPZ-6438 having the following formula:



(EPZ-6438) or a pharmaceutically acceptable salt thereof;

wherein the standard of care agent is selected from GDC0068, GSK1070916, GSK2126458, GSK690693, JQ1, Ruxolitinib, Enzastaurin, and GSK1070916.

16. The pharmaceutical composition of claim 1 for use in therapy.